Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Regulatory dendritic cells program B cells to differentiate into CD19hiFc IIbhi regulatory B cells through IFN-  and CD40L

(2012) L. Qian et al.   BLOOD

Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis

(2012) Linda Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B)

(2012) Emily L. Williams et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

The Herpes Simplex Virus 1 IgG Fc Receptor Blocks Antibody-Mediated Complement Activation and Antibody-Dependent Cellular Cytotoxicity In Vivo

(2011) J. M. Lubinski et al.   JOURNAL OF VIROLOGY

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

(2008) Arturo Molina   Annual Review of Medicine

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

(2008) M. Luqman et al.   BLOOD

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling

(2008) Claire A. Walshe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY